GlobalData on MSN14d
EC approves AstraZeneca’s Fasenra for EGPA treatment
The European Commission (EC) has approved AstraZeneca's Fasenra (benralizumab) as an add-on therapy for adults with relapsing ...
lifesciencesweden.se7d
AZ gets approval for drug targeting rare disease –it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.
Philippine News11d
Kris Aquino To Undergo New Medical Procedure
Kris Aquino is struggling with multiple autoimmune diseases and in addition to these health woes, is this condition.
Philippine News11d
Kris Aquino Recent Photo Show Drastic Weight Loss
KRIS AQUINO - The actress-host has just returned to the country and in her Halloween post, her massive weight loss is seen.
PharmiWeb15d
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...
Pharmabiz14d
European Union approves AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
PhilSTAR Life on MSN11d
Kris Aquino undergoing physical therapy after leg muscles became thin
Kris Aquino has started undergoing physical therapy after her leg muscles became thin amid her battle against her multiple autoimmune diseases. In a joint Instagram post by the actress' close friend ...
EuropaWire14d
AstraZeneca’s Fasenra Approved in EU for Treating Rare Vasculitis, Offering New Hope for EGPA Patients
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis ...
pharmaphorum8d
FDA says no to AZ's Fasenra for nasal polyp indication
Nucala – which is approved for severe asthma, Churg-Strauss syndrome and HES as well as CRSwNP – brought in $1.4 billion for GSK last year. A US district court has granted an injunction sought ...